Viridian: Positive Chronic TED Data Likely To Lead To BLA Filing In Second Half Of 2025 (Rating Upgrade)

Core Insights - Viridian Therapeutics (NASDAQ: VRDN) has reported positive results from its phase 3 THRIVE-2 study for its anti-IGF-1R drug veligrotug (VRDN-001), aimed at treating chronic thyroid eye disease (TED) [2] Company Overview - Viridian Therapeutics is focusing on the development of veligrotug, which has shown promising outcomes in clinical trials for TED [2] Market Context - The positive results from the THRIVE-2 study may position Viridian Therapeutics favorably in the biotech market, particularly in the treatment of thyroid eye disease [2]